[
  {
    "ts": null,
    "headline": "Has Dupixent Met Its Match? Rivals Nektar, Evommune Catapult On Eczema Results.",
    "summary": "Biotech stocks Nektar Therapeutics and Evommune launched Tuesday on positive results for their eczema treatments.",
    "url": "https://finnhub.io/api/news?id=fe8b2c354785c2e2ab450c2c69a5024c4c9ea0ab5b38b41cff9c628f6fb36dcd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770745332,
      "headline": "Has Dupixent Met Its Match? Rivals Nektar, Evommune Catapult On Eczema Results.",
      "id": 139033612,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Biotech stocks Nektar Therapeutics and Evommune launched Tuesday on positive results for their eczema treatments.",
      "url": "https://finnhub.io/api/news?id=fe8b2c354785c2e2ab450c2c69a5024c4c9ea0ab5b38b41cff9c628f6fb36dcd"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pipeline Progress Continues but Near-Term Visibility Remains Limited, RBC Says",
    "summary": "Regeneron Pharmaceuticals' (REGN) long-term prospects seem promising but there is still a lack of cl",
    "url": "https://finnhub.io/api/news?id=692fece1e6881c14ce1cfc4e4993a2ea27e95f9aaf615c6ec3b0c7820f04c466",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770742675,
      "headline": "Regeneron Pipeline Progress Continues but Near-Term Visibility Remains Limited, RBC Says",
      "id": 139033613,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Regeneron Pharmaceuticals' (REGN) long-term prospects seem promising but there is still a lack of cl",
      "url": "https://finnhub.io/api/news?id=692fece1e6881c14ce1cfc4e4993a2ea27e95f9aaf615c6ec3b0c7820f04c466"
    }
  },
  {
    "ts": null,
    "headline": "Evommune Nearly Doubles — Has Dupixent Met Its Match In Eczema?",
    "summary": "IPO stock Evommune roughly doubled Tuesday on positive results for its intravenously infused eczema treatment.",
    "url": "https://finnhub.io/api/news?id=447fbbf2034e7590dd08f507999359cc43954b794f307595d087bf72556c54bc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770732420,
      "headline": "Evommune Nearly Doubles — Has Dupixent Met Its Match In Eczema?",
      "id": 139032046,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "IPO stock Evommune roughly doubled Tuesday on positive results for its intravenously infused eczema treatment.",
      "url": "https://finnhub.io/api/news?id=447fbbf2034e7590dd08f507999359cc43954b794f307595d087bf72556c54bc"
    }
  },
  {
    "ts": null,
    "headline": "Nektar, continuing comeback, says eczema drug’s effects hold up in follow-up study",
    "summary": "The results vaulted Nektar’s market value to over $1 billion amid expectations the drug might prove a challenger to widely used medications like Dupixent.",
    "url": "https://finnhub.io/api/news?id=3eedf4b876764d5a39ea601ef81e41d4e40f6f3efc92c8566270779d4bf04b0b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770725580,
      "headline": "Nektar, continuing comeback, says eczema drug’s effects hold up in follow-up study",
      "id": 139033423,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "The results vaulted Nektar’s market value to over $1 billion amid expectations the drug might prove a challenger to widely used medications like Dupixent.",
      "url": "https://finnhub.io/api/news?id=3eedf4b876764d5a39ea601ef81e41d4e40f6f3efc92c8566270779d4bf04b0b"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Highlights Expanding Immunology Portfolio and Pipeline at AAAAI, Showcasing Novel Approaches to Treating Allergy",
    "summary": "36 abstracts to be presented across Regeneron-invented therapies, including first-time Phase 3 presentations for two distinct investigational allergen-blocking antibodies for cat and birch allergies New Dupixent® (dupilumab) data highlight its clinical and real-world impact across dermatological, respiratory and gastrointestinal diseases, including analyses of food allergy sensitization in children with atopic dermatitis TARRYTOWN, N.Y., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceutical",
    "url": "https://finnhub.io/api/news?id=b7c5d08c459ce2270057c9f7d301aac204b3950792dc6248b6a948420e9726e2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770724800,
      "headline": "Regeneron Highlights Expanding Immunology Portfolio and Pipeline at AAAAI, Showcasing Novel Approaches to Treating Allergy",
      "id": 139029714,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "36 abstracts to be presented across Regeneron-invented therapies, including first-time Phase 3 presentations for two distinct investigational allergen-blocking antibodies for cat and birch allergies New Dupixent® (dupilumab) data highlight its clinical and real-world impact across dermatological, respiratory and gastrointestinal diseases, including analyses of food allergy sensitization in children with atopic dermatitis TARRYTOWN, N.Y., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceutical",
      "url": "https://finnhub.io/api/news?id=b7c5d08c459ce2270057c9f7d301aac204b3950792dc6248b6a948420e9726e2"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron To Present 36 Immunology And Allergy Pipeline Abstracts At AAAAI, Featuring First Phase 3 Data On Cat And Birch Allergy Treatments And Dupixent Insights",
    "summary": "36 abstracts to be presented across Regeneron-invented therapies, including first-time Phase 3 presentations for two distinct investigational allergen-blocking antibodies for cat and birch allergiesNew Dupixent®",
    "url": "https://finnhub.io/api/news?id=591f6e4b35f82a21f87e9705ae617fe13120484192a82e0a6fa5eb687c89da5d",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770711204,
      "headline": "Regeneron To Present 36 Immunology And Allergy Pipeline Abstracts At AAAAI, Featuring First Phase 3 Data On Cat And Birch Allergy Treatments And Dupixent Insights",
      "id": 139030967,
      "image": "",
      "related": "REGN",
      "source": "Benzinga",
      "summary": "36 abstracts to be presented across Regeneron-invented therapies, including first-time Phase 3 presentations for two distinct investigational allergen-blocking antibodies for cat and birch allergiesNew Dupixent®",
      "url": "https://finnhub.io/api/news?id=591f6e4b35f82a21f87e9705ae617fe13120484192a82e0a6fa5eb687c89da5d"
    }
  }
]